BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 03, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Levadex: Extension study data

Data from the 12-month, open-label extension of the Phase III FREEDOM-301 trial showed that no Levadex-related serious adverse events were reported. More than 475 patients completed 6 months of Levadex treatment and over 250 patients completed 12 months of treatment. The extension study was conducted in support of an NDA submission...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >